Lexotanil (Bromazepam)

Bromazepam enhances the activity of the inhibitory neurotransmitter GABA by binding to a modulatory site on the GABA‑A receptor complex. This increases chloride ion flow into neurons, hyperpolarising the cell membrane and decreasing neuronal excitability, which results in anxiolytic, sedative, and muscle‑relaxant effects.

The appropriate dose of Lexotanil is individualized by the prescribing clinician based on the patient’s age, severity of anxiety, liver and kidney function, and response to therapy. The prescriber determines the starting dose, any titration steps, and the maximum daily amount, following local prescribing guidelines.

Safety of bromazepam in pregnancy and lactation has not been definitively established. It is generally avoided unless the potential benefit outweighs the risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To request Lexotanil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

Lexotanil (bromazepam) is a benzodiazepine with a relatively rapid onset and intermediate half‑life, offering effective short‑term anxiety relief. Compared with longer‑acting agents such as diazepam, bromazepam may produce less daytime sedation but still carries similar risks of dependence and withdrawal. Non‑benzodiazepine anxiolytics (e.g., buspirone) have different mechanisms and lower abuse potential but may act more slowly.

Lexotanil tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments. No refrigeration is required.

Lexotanil is taken orally. The tablet should be swallowed whole with a glass of water and may be taken with or without food, as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and avoid crushing or chewing the tablet unless specifically instructed.

Serious risks include the development of physical dependence and withdrawal syndrome after prolonged use, respiratory depression especially when combined with other central nervous system depressants, severe hypotension, paradoxical reactions such as agitation or aggression, and rare but potentially life‑threatening allergic reactions. Monitoring for these events is essential, particularly in high‑risk populations.

Lexotanil is contraindicated in individuals with known hypersensitivity to bromazepam or any benzodiazepine, patients with severe respiratory insufficiency, acute narrow‑angle glaucoma, and those who are currently intoxicated with alcohol or other depressants. Caution is also advised for the elderly, patients with hepatic or renal impairment, and anyone with a history of substance misuse.